• Something wrong with this record ?

CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy

K. Česká, J. Papež, H. Ošlejšková, O. Slabý, L. Radová, T. Loja, Z. Libá, A. Svěráková, M. Brázdil, Š. Aulická

. 2023 ; 46 (-) : 48-54. [pub] 20230615

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001257

OBJECTIVE: The pathophysiological processes leading to epileptogenesis and pharmacoresistance in epilepsy have been the subject of extensive preclinical and clinical research. The main impact on clinical practice is the development of new targeted therapies for epilepsy. We studied the importance of neuroinflammation in the development of epileptogenesis and pharmacoresistance in childhood epilepsy patients. METHODS: A cross-sectional study conducted at two epilepsy centers in the Czech Republic compared 22 pharmacoresistant patients and 4 pharmacodependent patients to 9 controls. We analyzed the ProcartaPlexTM 9-Plex immunoassay panel consisting of interleukin (IL)-6, IL-8, IL-10, IL-18, CXCL10/IP-10, monocyte chemoattractant protein 1 (CCL2/MCP-1), B lymphocyte chemoattractant (BLC), tumor necrosis factor-alpha (TNF-α), and chemokine (C-X3-X motif) ligand 1 (fractalkine/CXC3CL1) to determine their alterations in cerebrospinal fluid (CSF) and blood plasma, concurrently. RESULTS: The analysis of 21 paired CSF and plasma samples in pharmacoresistant patients compared to controls revealed a significant elevation of CCL2/MCP-1 in CSF (p < 0.000512) and plasma (p < 0.00.017). Higher levels of fractalkine/CXC3CL1 were revealed in the plasma of pharmacoresistant patients than in controls (p < 0.0704), and we determined an upward trend in CSF IL-8 levels (p < 0.08). No significant differences in CSF and plasma levels were detected between pharmacodependent patients and controls. CONCLUSION: Elevated CCL2/MCP-1 in CSF and plasma, elevated levels of fractalkine/CXC3CL1 in CSF, and a trend toward elevated IL-8 in the CSF of patients with pharmacoresistant epilepsy indicate these cytokines as potential biomarkers of epileptogenesis and pharmacoresistance. CCL2/MCP-1was detected in blood plasma; this assessment may be easily achieved in clinical practice without the invasiveness of a spinal tap. However, due to the complexity of neuroinflammation in epilepsy, further studies are warranted to confirm our findings.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001257
003      
CZ-PrNML
005      
20241121121945.0
007      
ta
008      
240109e20230615enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpn.2023.06.001 $2 doi
035    __
$a (PubMed)37429062
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Česká, Katarína $u Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy / $c K. Česká, J. Papež, H. Ošlejšková, O. Slabý, L. Radová, T. Loja, Z. Libá, A. Svěráková, M. Brázdil, Š. Aulická
520    9_
$a OBJECTIVE: The pathophysiological processes leading to epileptogenesis and pharmacoresistance in epilepsy have been the subject of extensive preclinical and clinical research. The main impact on clinical practice is the development of new targeted therapies for epilepsy. We studied the importance of neuroinflammation in the development of epileptogenesis and pharmacoresistance in childhood epilepsy patients. METHODS: A cross-sectional study conducted at two epilepsy centers in the Czech Republic compared 22 pharmacoresistant patients and 4 pharmacodependent patients to 9 controls. We analyzed the ProcartaPlexTM 9-Plex immunoassay panel consisting of interleukin (IL)-6, IL-8, IL-10, IL-18, CXCL10/IP-10, monocyte chemoattractant protein 1 (CCL2/MCP-1), B lymphocyte chemoattractant (BLC), tumor necrosis factor-alpha (TNF-α), and chemokine (C-X3-X motif) ligand 1 (fractalkine/CXC3CL1) to determine their alterations in cerebrospinal fluid (CSF) and blood plasma, concurrently. RESULTS: The analysis of 21 paired CSF and plasma samples in pharmacoresistant patients compared to controls revealed a significant elevation of CCL2/MCP-1 in CSF (p < 0.000512) and plasma (p < 0.00.017). Higher levels of fractalkine/CXC3CL1 were revealed in the plasma of pharmacoresistant patients than in controls (p < 0.0704), and we determined an upward trend in CSF IL-8 levels (p < 0.08). No significant differences in CSF and plasma levels were detected between pharmacodependent patients and controls. CONCLUSION: Elevated CCL2/MCP-1 in CSF and plasma, elevated levels of fractalkine/CXC3CL1 in CSF, and a trend toward elevated IL-8 in the CSF of patients with pharmacoresistant epilepsy indicate these cytokines as potential biomarkers of epileptogenesis and pharmacoresistance. CCL2/MCP-1was detected in blood plasma; this assessment may be easily achieved in clinical practice without the invasiveness of a spinal tap. However, due to the complexity of neuroinflammation in epilepsy, further studies are warranted to confirm our findings.
650    _2
$a lidé $7 D006801
650    12
$a chemokin CCL2 $x mozkomíšní mok $7 D018932
650    _2
$a interleukin-8 $x mozkomíšní mok $7 D016209
650    _2
$a chemokin CX3CL1 $7 D054428
650    _2
$a neurozánětlivé nemoci $7 D000090862
650    _2
$a průřezové studie $7 D003430
650    12
$a epilepsie $x diagnóza $x farmakoterapie $7 D004827
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
655    _2
$a časopisecké články $7 D016428
700    1_
$a Papež, Jan $u Department of Pediatrics, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ošlejšková, Hana $u Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Slabý, Ondřej $u Ondrej Slaby Research Group, Central European Institute of Technology, Brno, Czech Republic
700    1_
$a Radová, Lenka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Loja, Tomáš $u Ondrej Slaby Research Group, Central European Institute of Technology, Brno, Czech Republic
700    1_
$a Libá, Zuzana $u Department of Pediatric Neurology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Czech Republic
700    1_
$a Svěráková, Anna $u Department of Pediatric Neurology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Czech Republic $7 xx0325882
700    1_
$a Brázdil, Milan $u Brno Epilepsy Center, Department of Neurology, St. Anne's University Hospital and Medical Faculty of Masaryk University, Full-member of ERN, EpiCARE, Brno, Czech Republic
700    1_
$a Aulická, Štefánia $u Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Pediatrics, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Ondrej Slaby Research Group, Central European Institute of Technology, Brno, Czech Republic; Division of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. Electronic address: stefania.aulicka@gmail.com
773    0_
$w MED00149836 $t European journal of paediatric neurology $x 1532-2130 $g Roč. 46 (20230615), s. 48-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37429062 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20241121121939 $b ABA008
999    __
$a ok $b bmc $g 2049711 $s 1210951
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 46 $c - $d 48-54 $e 20230615 $i 1532-2130 $m European journal of paediatric neurology $n Eur J Paediatr Neurol $x MED00149836
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options